Recombinant Api m3 Allergen for Safer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergen preparations for specific immunotherapy are limited by potential systemic reactions and require lengthy treatment periods, necessitating the development of modified allergens with reduced allergenic activity for safer and more effective desensitization therapy.
Innovation Solution
A recombinant polypeptide with a homology of more than 70% to the amino acid sequence of Api m3, encoded by a nucleic acid, is used to bind IgE antibodies, allowing for the development of hypoallergenic molecules that can stimulate T-cell responses and induce long-lasting protective immune responses without severe side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current allergen preparations are used for specific immunotherapy, then immunogenicity is maintained, but systemic reactions occur and treatment periods become lengthy
Solution Approach 1:
The patent applies parameter changes by modifying the allergen's molecular structure through point mutations in the Api m 3 protein sequence. Specifically, amino acid substitutions are introduced to reduce IgE binding affinity while preserving T-cell epitopes, thereby changing the immunological parameters of the allergen to achieve safer and more efficient immunotherapy
2Reliability
If allergen preparations are used for desensitization therapy, then immune response is stimulated, but severe allergic reactions may occur
Solution Approach 1:
The patent applies local quality by making site-specific modifications to the Api m 3 allergen structure. Point mutations are introduced at specific amino acid positions that are involved in IgE binding, while leaving other regions of the protein intact to maintain T-cell recognition and immunogenicity
Solution Approach 2:
The patent converts the harmful allergenic activity of Api m 3 into a beneficial therapeutic effect by reducing its ability to bind IgE antibodies while preserving its ability to stimulate protective immune responses. The modified allergen becomes less harmful but remains effective for desensitization therapy
3Object-affected harmful factors
If native Api m 3 allergen is used, then strong IgE binding occurs causing allergic reactions, but effective desensitization can be achieved
Solution Approach 1:
The patent applies segmentation by separating the different functional regions of the Api m 3 protein. The IgE binding domains are modified through point mutations to reduce allergenicity, while the T-cell epitope regions are preserved to maintain therapeutic effectiveness. This functional segmentation allows independent optimization of safety and efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant polypeptide effectively reduces allergenicity while maintaining immunogenicity, providing a safer and more effective route for specific immunotherapy by modulating immune responses and preventing severe allergic reactions.
Implementation Method 1
A recombinant polypeptide with a homology of more than 70% to the amino acid sequence of Api m3, encoded by a nucleic acid, is used to bind IgE antibodies
Data Source
AI summary
The present invention relates to a recombinant polypeptide capable of binding to IgE from subjects allergic to venom of an insect from the order Hymenoptera having a homology of more than 70% to the amino acid sequence of SEQ ID NO: 2, which is the honey bee allergen Api m3 (acid phosphatase). The invention further relates to nucleic acid encoding the polypeptide, expression vectors, host cells and methods of preparing the polypeptide, as well as diagnostic and pharmaceutical uses thereof.